What is CLRB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CLRB?

P/E (TTM) is n/a and 52-week range is $1.34 to $5.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CLRB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CLRB?

The company profile lists revenue (TTM) near $93K, net income (TTM) near $-2.31B, EPS (TTM) near $-4.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cellectar Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Florham Park, New Jersey, US, 8M shares outstanding, ISIN US15117F8804 when available from company profile and filing metadata.

Cellectar Biosciences Inc

$CLRB

Health Care · Biotechnology

IR Run Scenarios

$1.45

+3.57%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Employees

Website

www.cellectar.com/

IPO

2005-05-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)